Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Abvc Biopharma (ABVC) over the last 12 years, with Q3 2025 value amounting to $1.1 million.

  • Abvc Biopharma's Cash from Financing Activities rose 149190.1% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 12718.15%. This contributed to the annual value of $2.0 million for FY2024, which is 4881.68% down from last year.
  • Abvc Biopharma's Cash from Financing Activities amounted to $1.1 million in Q3 2025, which was up 149190.1% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's Cash from Financing Activities ranged from a high of $5.8 million in Q3 2021 and a low of -$253500.0 during Q4 2022
  • In the last 5 years, Abvc Biopharma's Cash from Financing Activities had a median value of $603500.0 in 2022 and averaged $1.2 million.
  • Per our database at Business Quant, Abvc Biopharma's Cash from Financing Activities crashed by 10711.12% in 2021 and then soared by 263951.31% in 2024.
  • Over the past 5 years, Abvc Biopharma's Cash from Financing Activities (Quarter) stood at $4.3 million in 2021, then crashed by 105.96% to -$253500.0 in 2022, then skyrocketed by 115.16% to $38421.0 in 2023, then surged by 774.06% to $335822.0 in 2024, then surged by 237.2% to $1.1 million in 2025.
  • Its Cash from Financing Activities stands at $1.1 million for Q3 2025, versus $1.9 million for Q2 2025 and $428756.0 for Q1 2025.